Xiaoxin Meng
Papers
2
Total Citations
26
H-Index
2
About
Xiaoxin Meng is a distinguished urologic oncologist whose research has significantly advanced the management of kidney and prostate cancers. Dr. Meng’s primary contributions lie in the comparative effectiveness of minimally invasive treatments for renal masses and the characterization of rare prostate malignancies. His landmark 2014 systematic review and meta-analysis, cited 22 times, critically evaluated radiofrequency ablation versus partial nephrectomy for clinical stage 1 renal tumors, providing pivotal evidence that helped shape treatment paradigms for small renal masses. More recently, Dr. Meng has focused on ultra-rare prostate cancers, as demonstrated by his 2022 single-center study on primary prostatic signet ring cell carcinoma (PPSRCC). Drawing from the First Affiliated Hospital of Nanjing Medical University, this work offers essential clinical guidance on diagnosing and managing this aggressive subtype, contributing valuable data to an area with limited literature. Through these investigations, Dr. Meng has established himself as a key voice in evidence-based urologic oncology, bridging the gap between surgical innovation and rare disease management.
Research Focus
Key Achievements
Top Papers
- 1
- 2